Holzer & Holzer, LLC is investigating whether Once Upon a Farm, PBC complied with federal securities laws following the company's recall of its Tractor Wheels soft-baked bars due to choking incidents reported to the FDA. The recall announcement caused the company's stock price to drop. Investors who suffered losses are encouraged to contact the law firm to discuss their legal rights. This investigation highlights potential legal and financial risks for the company and its shareholders.
Once Upon a Farm is under investigation following a product recall and stock price drop. For readers following the Consumer Staples sector, here is Pluang's market snapshot as of Nov 05, 2026 00:11 WIB: Of 63 priced US stocks, 57 rose and 4 fell. Notable movers include XXII down 20.50% at USD 0.04 with a typical hold time of 27 days and a 95% buy order activity, Dollar Tree up 10.18% at USD 147.72 with a 59-day hold time, and Vita Coco up 9.65% at USD 65.45 with a 12-day hold time.
Goldman Sachs Group, Inc. disclosed that it briefly held a combined stake exceeding 3% in Ontex Group NV shares as of October 27, 2026, with 566,115 voting rights and 1,965,157 financial instruments. However, by October 28, 2026, their combined posit...
BNP Paribas announced its monthly declaration of voting rights and shares as of October 31, 2026. The bank reported a total of 1,101,600,607 shares and an equal number of voting rights. This update is part of regulatory compliance under French commer...
Ontex disclosed that Goldman Sachs Group, Inc. crossed the 3% ownership threshold in Ontex shares on October 27, 2026, holding a combined total of 3.07% including voting rights and financial instruments. However, the next day, October 28, 2026, Goldm...
Neion Bio has appointed John A. Maga, Ph.D., as Head of Biologics and CMC to lead the development of biologic medicines using its Raptor platform, which produces proteins in transgenic chicken eggs. Maga brings over 25 years of biopharmaceutical expe...
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
